دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In The Literature
doi : 10.1093/cid/ciac092
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages i–ii
Improving Outpatient Antibiotic Prescribing for Respiratory Tract Infections in Primary Care: A Stepped-Wedge Cluster Randomized Trial
Lauren Dutcher, Kathleen Degnan, Afia B Adu-Gyamfi, Ebbing Lautenbach, Leigh Cressman, Michael Z David, Valerie Cluzet, Julia E Szymczak, David A Pegues, Warren Bilker, Pam Tolomeo, Keith W Hamilton
doi : 10.1093/cid/ciab602
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 947–956
Inappropriate antibiotic prescribing is common in primary care (PC), particularly for respiratory tract diagnoses (RTDs). However, the optimal approach for improving prescribing remains unknown.
Conditional Cash Transfers to Incentivize Tuberculosis Screening: Description of a Novel Strategy for Contact Investigation in Rural South Africa
Yeonsoo Baik, Colleen F Hanrahan, Lesego Mmolawa, Bareng A S Nonyane, Nicholas W Albaugh, Limakatso Lebina, Tsundzukani Siwelana, Neil Martinson, David W Dowdy
doi : 10.1093/cid/ciab601
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 957–964
Providing incentives to screen close contacts for tuberculosis (TB) is an alternative to household-based contact investigation. We aimed to characterize patients and contexts where this incentive-based strategy might be preferred.
Evaluation of the Infectious Diseases Society of America’s Core Antimicrobial Stewardship Curriculum for Infectious Diseases Fellows
Jennifer O Spicer, Wendy S Armstrong, Brian S Schwartz, Lilian M Abbo, Sonali D Advani, Alice E Barsoumian, Cole Beeler, Kenza Bennani, Marisa Holubar, Misha Huang, Dilek Ince, Julie Ann Justo, Matthew S L Lee, Ashleigh Logan, Conan MacDougall, Priya Nori, Christopher Ohl, Payal K Patel, Paul S Pottinger, Rachel Shnekendorf, Conor Stack, Trevor C Van Schooneveld, Zachary I Willis, Yuan Zhou, Vera P Luther
doi : 10.1093/cid/ciab600
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 965–972
Despite widespread availability of curative therapy, tuberculosis (TB) treatment outcomes remain suboptimal. Clinical prediction models can inform treatment strategies to improve outcomes. Using baseline clinical data, we developed a prediction model for unsuccessful TB treatment outcome and evaluated the incremental value of human immunodeficiency virus (HIV)–related severity and isoniazid acetylator status.
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes
Lauren S Peetluk, Peter F Rebeiro, Felipe M Ridolfi, Bruno B Andrade, Marcelo Cordeiro-Santos, Afranio Kritski, Betina Durovni, Solange Calvacante, Marina C Figueiredo, David W Haas, Dandan Liu, Valeria C Rolla, Timothy R Sterling, Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Network
doi : 10.1093/cid/ciab598
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 973–982
Despite widespread availability of curative therapy, tuberculosis (TB) treatment outcomes remain suboptimal. Clinical prediction models can inform treatment strategies to improve outcomes. Using baseline clinical data, we developed a prediction model for unsuccessful TB treatment outcome and evaluated the incremental value of human immunodeficiency virus (HIV)–related severity and isoniazid acetylator status.
Health-Economic Value of Vaccination Against Group A Streptococcus in the United States
Kristin Andrejko, Lilith K Whittles, Joseph A Lewnard
doi : 10.1093/cid/ciab597
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 983–992
Vaccines are needed to reduce the burden of group A Streptococcus (GAS). We assessed the potential health-economic value of GAS vaccines achievable through prevention of invasive disease and acute upper respiratory infections in the United States.
Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships
Damien C Tully, Judith A Hahn, David J Bean, Jennifer L Evans, Meghan D Morris, Kimberly Page, Todd M Allen
doi : 10.1093/cid/ciab596
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 993–1003
The current opioid epidemic across the United States has fueled a surge in the rate of new hepatitis C virus (HCV) infections among young persons who inject drugs (PWIDs). Paramount to interrupting transmission is targeting these high-risk populations and understanding the underlying network structures facilitating transmission within these communities.
Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020
Angela R Branche, Lisa Saiman, Edward E Walsh, Ann R Falsey, William D Sieling, William Greendyke, Derick R Peterson, Celibell Y Vargas, Matthew Phillips, Lyn Finelli
doi : 10.1093/cid/ciab595
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1004–1011,
Respiratory syncytial virus (RSV) causes acute respiratory illness (ARI) and triggers exacerbations of cardiopulmonary disease. Estimates of incidence in hospitalized adults range widely, with few data on incidence in adults with comorbidities that increase the risk of severity. We conducted a prospective, population-based, surveillance study to estimate incidence of RSV hospitalization among adults overall and those with specific comorbidities.
Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort
Lorenza N C Dezanet, Raisha Kassime, Patrick Miailhes, Caroline Lascoux-Combe, Julie Chas, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Constance Delaugerre, Karine Lacombe, Anders Boyd
doi : 10.1093/cid/ciab594
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1012–1021
In individuals living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV), widespread tenofovir (TDF)–containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the links between viral replication, liver fibrosis, and mortality remain unclear.
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Yuani M Roman, Paula Alejandra Burela, Vinay Pasupuleti, Alejandro Piscoya, Jose E Vidal, Adrian V Hernandez
doi : 10.1093/cid/ciab591
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1022–1029
We systematically assessed benefits and harms of the use of ivermectin (IVM) in patients with coronavirus disease 2019 (COVID-19).
Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study
Issaka Sagara, John Woodford, Mamady Kone, Mahamadoun Hamady Assadou, Abdoulaye Katile, Oumar Attaher, Amatigue Zeguime, M’Bouye Doucoure, Emily Higbee, Jacquelyn Lane, Rathy Mohan, Justin Doritchamou, Irfan Zaidi, Dominic Esposito, Jennifer Kwan, Kaitlyn Sadtler, Alassane Dicko, Patrick E Duffy
doi : 10.1093/cid/ciab589
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1030–1038
The extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure and transmission in Mali and the surrounding region is not well understood. We aimed to estimate the cumulative incidence of SARS-CoV-2 in 3 communities and understand factors associated with infection.
Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Clusters Based on Integrated Genomic Surveillance, Outbreak Analysis and Contact Tracing in an Urban Setting
Andreas Walker, Torsten Houwaart, Patrick Finzer, Lutz Ehlkes, Alona Tyshaieva, Maximilian Damagnez, Daniel Strelow, Ashley Duplessis, Jessica Nicolai, Tobias Wienemann, Teresa Tamayo, Malte Kohns Vasconcelos, Lisanna Hülse, Katrin Hoffmann, Nadine Lübke, Sandra Hauka, Marcel Andree, Martin P Däumer, Alexander Thielen, Susanne Kolbe-Busch, Klaus Göbels, Rainer Zotz, Klaus Pfeffer, Jörg Timm, Alexander T Dilthey, German COVID-19 OMICS Initiative (DeCOI)
doi : 10.1093/cid/ciab588
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1039–1046,
Tracing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission chains is still a major challenge for public health authorities, when incidental contacts are not recalled or are not perceived as potential risk contacts. Viral sequencing can address key questions about SARS-CoV-2 evolution and may support reconstruction of viral transmission networks by integration of molecular epidemiology into classical contact tracing.
Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants
Louise Kuhn, Maria Paximadis, Bianca Da Costa Dias, Yanhan Shen, Sizanani Mncube, Renate Strehlau, Stephanie Shiau, Faeezah Patel, Megan Burke, Karl-Günter Technau, Gayle Sherman, Shayne Loubser, Elaine J Abrams, Caroline T Tiemessen
doi : 10.1093/cid/ciab586
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1047–1054
Younger age of antiretroviral therapy (ART) initiation is associated with smaller viral reservoirs in perinatally acquired HIV-1 infection, but there is wide variability among early-treated infants. Predictors of this variability are not fully described.
Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014–2018
R Paul McClung, Alexandra M Oster, M Cheryl Bañez Ocfemia, Neeraja Saduvala, Walid Heneine, Jeffrey A Johnson, Angela L Hernandez
doi : 10.1093/cid/ciab583
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1055–1062
Transmitted human immunodeficiency virus (HIV) drug resistance can threaten the efficacy of antiretroviral therapy and pre-exposure prophylaxis (PrEP). Drug-resistance testing is recommended at entry to HIV care in the United States and provides valuable insight for clinical decision making and population-level monitoring.
Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience
John Paul Verderese, Maria Stepanova, Brian Lam, Andrei Racila, Andrej Kolacevski, David Allen, Erin Hodson, Bahareh Aslani-Amoli, Michael Homeyer, Sarah Stanmyre, Helen Stevens, Stephanie Garofalo, Linda Henry, Chapy Venkatesan, Lynn H Gerber, Steve J Motew, J Stephen Jones, Zobair M Younossi
doi : 10.1093/cid/ciab579
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1063–1069
Neutralizing monoclonal antibody (NmAb) treatments have received Emergency Use Authorization to treat patients with mild or moderate COVID-19 infection. To date, no real- world data on the efficacy of NmAbs have been reported from clinical practice. We assessed the impact of NmAb treatment given in the outpatient clinical practice setting on hospital utilization.
Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States
Richard E Nelson, David Hyun, Amanda Jezek, Matthew H Samore
doi : 10.1093/cid/ciab696
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1070–1080
This study reports estimates of the healthcare costs, length of stay, and mortality associated with infections due to multidrug-resistant bacteria among elderly individuals in the United States.
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival
Upasana Das Adhikari, George Eng, Mara Farcasanu, Laura E Avena, Manish C Choudhary, Virginia A Triant, Meaghan Flagg, Abigail E Schiff, Isabella Gomez, Leah M Froehle, Thomas J Diefenbach, Larance Ronsard, Daniel Lingwood, Grace C Lee, Seyed Alireza Rabi, Derek Erstad, George Velmahos, Jonathan Z Li, Richard Hodin, James R Stone, Anna N Honko, Anthony Griffiths, Ömer H Yilmaz, Douglas S Kwon
doi : 10.1093/cid/ciab623
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1081–1084
The clinical significance of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) RNA in stool remains uncertain. We found that extrapulmonary dissemination of infection to the gastrointestinal tract, assessed by the presence of SARS-CoV-2 RNA in stool, is associated with decreased coronavirus disease 2019 (COVID-19) survival. Measurement of SARS-CoV-2 RNA in stool may have utility for clinical risk assessment.
Coronavirus Disease 2019 (COVID-19) Outbreak Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) P.1 Lineage in a Long-Term Care Home After Implementation of a Vaccination Program—Ontario, Canada, April–May 2021
Chantal Williams, Dana Al-Bargash, Celeste Macalintal, Rebecca Stuart, Anu Seth, Julienne Latham, Leah Gitterman, Stephanie Fedsin, Marion Godoy, Robert Kozak, Jennifer L Guthrie, Heidi Wood, Allison McGeer, Susy Hota, Elizabeth Rea
doi : 10.1093/cid/ciab617
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1085–1088
In a P.1 coronavirus disease 2019 (COVID-19) outbreak in a long-term care home, vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was 52.5% (95% confidence interval: 26.9%–69.1%) in residents and 66.2% (2.3%–88.3%) in staff. Vaccine effectiveness against severe illness was 78.6% (47.9%–91.2%) in residents. Two of 19 vaccinated resident case patients died. Outbreak management required both vaccination and infection control measures.
Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State
Abbye E McEwen, Seth Cohen, Chloe Bryson-Cahn, Catherine Liu, Steven A Pergam, John Lynch, Adrienne Schippers, Kathy Strand, Estella Whimbey, Nandita S Mani, Allison J Zelikoff, Vanessa A Makarewicz, Elizabeth R Brown, Shah A Mohamed Bakhash, Noah R Baker, Jared Castor, Robert J Livingston, Meei-Li Huang, Keith R Jerome, Alexander L Greninger, Pavitra Roychoudhury
doi : 10.1093/cid/ciab581
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1089–1092
Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOCs) and had a median Ct of 20.2 (IQR, 17.1–23.3). When compared with 5174 contemporaneous samples sequenced in our laboratory, VOCs were significantly enriched among breakthrough infections (P < .05).
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients
Alessandra Mazzola, Eve Todesco, Sarah Drouin, Fanny Hazan, Stéphane Marot, Dominique Thabut, Shaida Varnous, Cathia Soulié, Benoît Barrou, Anne-Geneviève Marcelin, Filomena Conti
doi : 10.1093/cid/ciab580
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1093–1096
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.
The Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission from Patients With Undiagnosed Coronavirus Disease 2019 (COVID-19) to Roommates in a Large Academic Medical Center
Abraar Karan, Michael Klompas, Robert Tucker, Meghan Baker, Vineeta Vaidya, Chanu Rhee
doi : 10.1093/cid/ciab564
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1097–1100
We assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission between patients in shared rooms in an academic hospital between September 2020 and April 2021. In total, 11 290 patients were admitted to shared rooms, of whom 25 tested positive. Among 31 exposed roommates, 12 (39%) tested positive within 14 days. Transmission was associated with polymerase chain reaction (PCR) cycle thresholds ≤21.
Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus
Amelia J Davis, Meredith Greene, Eugenia Siegler, Kathleen V Fitch, Sarah A Schmalzle, Alysa Krain, Jaime H Vera, Marta Boffito, Julian Falutz, Kristine M Erlandson
doi : 10.1093/cid/ciab682
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1101–1106
s care of persons living with human immunodeficiency virus (HIV; PWH) has transitioned from management of opportunistic infections to management of conditions associated with older age, new models of geriatric consultation are needed. The authors, who represent 9 clinics across North America and the United Kingdom, provided their insights on models of geriatric consultation for older PWH. Three models of geriatric consultation are delineated: outpatient referral/consultation, combined HIV/geriatric multidisciplinary clinic, and dually trained providers within 1 clinical setting. A patient-centered approach and the use of expertise across disciplines were universally identified as strengths.
Urgent, Comprehensive Federal Action Needed To Stem Mortality and Medicare Costs Associated With Antimicrobial Resistance
Vance G Fowler, Jr, Amanda Jezek, Emily S Spivak, Kathy Talkington
doi : 10.1093/cid/ciab697
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1107–1111
This paper is a call to action for the policies necessary to reduce the burden of antimicrobial resistance, including federal investments in antibiotic stewardship, antibiotic innovation, surveillance, research, diagnostics, infection prevention, the infectious diseases workforce, and global coordination.
The Value of Medical Registries and Observational Studies Early in Pandemics: The Coronavirus Disease 2019 (COVID-19) Experience
Somaya Albhaisi, Richard P Wenzel
doi : 10.1093/cid/ciab634
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1112–1116
Whereas randomized clinical trials remain the gold standard for evaluating new therapies for infections, we argue that registries and observational studies early in the coronavirus disease 2019 (COVID-19) pandemic provided invaluable understanding of the natural history and preliminary data on risk factors and possible treatments
A 70-Year-Old Man With Fever and Fatigue
Qing-luan Yang, Sheng-lei Yu, Ling-yun Shao, Qiao-ling Ruan, Wen-hong Zhang
doi : 10.1093/cid/ciab119
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1117–1119
Effect of Ivermectin in the Treatment of Coronavirus Disease 2019: A Trial Sequential Analysis Highlights the Requirement of Additional Randomized, Controlled Trials
Sunali Padhi, Abhijit Pati, Aditya K Panda
doi : 10.1093/cid/ciab692
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1120–1121
Need for More Randomized Controlled Trials With Rigorous Methodology to Confirm That Ivermectin Is Not a Viable Option for the Treatment of Coronavirus Disease 2019
Masahiro Banno, Yasushi Tsujimoto, Masahiro Ishikane
doi : 10.1093/cid/ciab689
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1121–1122
Reply to Banno et al and Padhi et al
Adrian V Hernandez, Yuani M Roman, Paula A Burela, Vinay Pasupuleti, Alejandro Piscoya, Jose E Vidal
doi : 10.1093/cid/ciab693
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1122–1123
Differential Anti-S Antibody Titers in Vaccinated Residents During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 (β) in an Elderly Nursing Home
Slim Fourati, Benoit Bailly, Anne Le Bouter, Luc Guilpain, Christophe Rodriguez, Jean-Michel Pawlotsky
doi : 10.1093/cid/ciab676
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1123–1124
Letter to the Editor: Persisting Health Disparities in Women Living with HIV from the US
Philip E Castle
doi : 10.1093/cid/ciab675
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1124–1125
Corrigendum to: Toxoplasmosis Outbreak Associated With Toxoplasma gondii-Contaminated Venison—High Attack Rate, Unusual Clinical Presentation, and Atypical Genotype
Amy C Schumacher, Lina I Elbadawi, Traci DeSalvo, Anne Straily, Daniel Ajzenberg, David Letzer, Ellen Moldenhauer, Tammy L Handly, Dolores Hill, Marie-Laure Dardé, Christelle Pomares, Karine Passebosc-Faure, Kristine Bisgard, Carlos A Gomez, Cindy Press, Stephanie Smiley, José G Montoya, James J Kazmierczak
doi : 10.1093/cid/ciab798
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Page 1126
Corrigendum to: Effectiveness of 3 Versus 6 ft of Physical Distancing for Controlling Spread of Coronavirus Disease 2019 Among Primary and Secondary Students and Staff: A Retrospective, Statewide Cohort Study
Polly van den Berg, Elissa M Schechter-Perkins, Rebecca S Jack, Isabella Epshtein, Richard Nelson, Emily Oster, Westyn Branch-Elliman
doi : 10.1093/cid/ciab1049
Clinical Infectious Diseases, Volume 74, Issue 6, 15 March 2022, Pages 1127–1129
